Fenofibrate is a PPAR-alpha agonist (fibrate) indicated for severe hypertriglyceridemia and primary hypercholesterolemia or mixed dyslipidemia. We supply it to US manufacturers of tablets and capsules.
Data from PubChem (CID 3339) and FDA’s substance registry
CAS number
49562-28-9
Molecular formula
C20H21ClO4
Molecular weight
360.8g/mol
FDA UNII
IUPAC name
propan-2-yl 2-[4-(4-chlorobenzoyl)phenoxy]-2-methylpropanoate
InChIKey
YMTINGFKWWXKFG-UHFFFAOYSA-N
- Appearance
- White or almost white crystalline powder, melting at 79 to 82 °C.
- Solubility
- Insoluble in water.
Typical description, from FDA-approved labeling and pharmacopoeial monographs. The specification sent with your quote is the controlling document for any source.
Worth settling with your inquiry
Bioavailability depends on particle size, which is why approved products come in so many strengths. State whether your formulation starts from standard or micronized material.
On the US market
- Reference product
- TricorNDA 019304
- Approved ANDAs
- 37 with a marketed product
- Approved forms and strengths
- Tablet 40 mg to 160 mg, in 7 strengths
- Capsule 43 mg to 200 mg, in 7 strengths
Single-ingredient products in FDA’s Drugs@FDA database, retrieved November 2026. The brand name belongs to its owner and identifies the reference product only.
Grade
USP or Ph. Eur. where a monograph exists, or your own specification.
Quantities
From development quantities for formulation work to commercial supply.
Packaging
To the manufacturer’s standard, typically fiber or HDPE drums with double polyethylene liners.
Regulatory filings
US DMF and CEP availability depends on the source. We confirm the filing status in writing with the quotation.
Documents available with a quote
- Specification and certificate of analysis
- Safety data sheet
- Method of analysis
- DMF letter of authorization, where a US DMF is filed
- GMP certificate and inspection history of the site
- Residual solvents and elemental impurities statements
- Nitrosamine risk assessment
- TSE/BSE statement
Need something else for your QA file? Email info@yogpharma.com